Amgen (AMGN) Tops Q2 EPS by 10c; Boosts FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Leerink Partners Remains Sidelined on Amgen (AMGN) Following 2Q
July 28, 2016 7:18 AM EDTLeerink Partners reiterated a Market Perform rating on Amgen (NASDAQ: AMGN), and raised the price target to $201.00 (from $186.00), following the company's 2Q earnings report. AMGN reported total revenues of $5.69bn, beating consensus by 3%. The company also reported an operating margin of 51% on expenses of $2.876bn, which was in-line with consensus.
Analyst Geoffrey C. Porges commented, "Amgen Reported Q2 Results Beating Consensus for Revenue by 2% and Beating by 3% on EPS. Total revenue of $5.69bn included $5.474bn in product sales that beat consensus by 3% and missed our estimate by -2%. As with the... More
Amgen (AMGN) PT Raised to $190 at BMO Capital
July 28, 2016 6:46 AM EDTBMO Capital analyst M. Ian Somaiya reiterated an Outperform rating and raised his price target on Amgen (NASDAQ: AMGN) to $190.00 (from $186.00) following top and bottom line beat in Q2.
Somaiya commented, "We are raising our price target on the AMGN shares to $190... More
